New Dual-Target CAR t therapy tackles tough blood cancers
Disease control
Recruiting now
This early-phase study tests a new treatment called BCMA-CD19 cCAR for people with multiple myeloma or plasmacytoid lymphoma that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target two cancer markers (BCMA and…
Phase: PHASE1 • Sponsor: iCell Gene Therapeutics • Aim: Disease control
Last updated Jun 15, 2026 19:07 UTC